MicroRNA-320a acts as a tumor suppressor in endometrial carcinoma by targeting IGF-1R

Shu,Shanrong; Liu,Xiaoping; Xu,Ming; Gao,Xuesong; Chen,Shu; Zhang,Lai; Li,Ruiman

doi:10.3892/ijmm.2019.4051

MicroRNA-320a acts as a tumor suppressor in endometrial carcinoma by targeting IGF-1R

Authors:
- Shanrong Shu
- Xiaoping Liu
- Ming Xu
- Xuesong Gao
- Shu Chen
- Lai Zhang
- Ruiman Li
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, P.R. China, Department of Hematology, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong 510630, P.R. China, Department of Medical Ultrasound, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510080, P.R. China, Department of Clinical Medicine, Medical College of Jinan University, Guangzhou, Guangdong 510630, P.R. China
Published online on: January 7, 2019 https://doi.org/10.3892/ijmm.2019.4051
Pages: 1505-1512

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dysregulation of microRNAs (miRs) is implicated in the carcinogenesis of various types of malignant tumor by manipulating cell growth and apoptosis. Abnormal expression of miR‑320a is involved in tumorigenesis of many types of cancer. The potential association of miR‑320a and the possible regulatory mechanisms in endometrial carcinoma is rarely elucidated. In the present study, it was demonstrated that miR‑320a expression was decreased in endometrial carcinoma tissues and cell lines. The present results also indicated that overexpression of miR‑320a suppressed cell proliferation through inducing G2/M phrase arrest and apoptosis. Insulin‑like growth factor receptror‑1 (IGF‑1R) was verified to be the potential target of miR‑320a by computational analysis and luciferase reporter assays. In addition, overexpression of miR‑320a reduced endogenous IGF‑1R expression in cells. Furthermore, it was demonstrated that upregulation of miR‑320a inhibited phosphorylated (p)‑protein kinase B and p‑mechanistic target of rapamycin activation and promoted B cell lymphoma‑2‑associated death promoter expression. Reintroduction of IGF‑1R into miR‑320a‑overexpressed cells antagonized the impact of miR‑320a on its downstream protein, which demonstrated that the tumor suppressive role of miR‑320a in endometrial carcinoma is exerted by the signal pathway mediated by IGF‑1R. It was therefore concluded that miR‑320a served an anti‑tumor role on endometrial carcinoma through the regulation of IGF‑1R, and miR‑320a may be used as the target for the gene therapy of endometrial carcinoma.

View Figures

View References

1	Sanni OB, Mc Menamin ÚC, Cardwell CR, Sharp L, Murray LJ and Coleman HG: Commonly used medications and endometrial cancer survival: A population-based cohort study. Br J Cancer. 117:432–438. 2017. View Article : Google Scholar : PubMed/NCBI
2	Pautier P and Pommeret F: Systemic therapy for advanced endometrial cancer. Bull Cancer. 104:1046–1053. 2017.In French. View Article : Google Scholar : PubMed/NCBI
3	Ballester M, Bendifallah S and Daraï E: European guidelines (ESMO-ESGO-ESTRO consensus conference) for the management of endometrial cancer. Bull Cancer. 104:1032–1038. 2017.In French. View Article : Google Scholar : PubMed/NCBI
4	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
5	Stope MB, Koensgen D, Weimer J, Paditz M, Burchardt M, Bauerschlag D and Mustea A: The future therapy of endometrial cancer: microRNA's functionality, capability, and putative clinical application. Arch Gynecol Obstet. 294:889–895. 2016. View Article : Google Scholar : PubMed/NCBI
6	Ramón LA, Braza-Boïls A, Gilabert J, Chirivella M, España F, Estellés A and Gilabert-Estellés J: microRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer. Hum Reprod. 27:3036–3045. 2012. View Article : Google Scholar : PubMed/NCBI
7	Park YA, Lee JW, Choi JJ, Jeon HK, Cho Y, Choi C, Kim TJ, Lee NW, Kim BG and Bae DS: The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma. Gynecol Oncol. 124:125–133. 2012. View Article : Google Scholar
8	Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF, Siu NS, Wong YM, Tsang PT, Pang MW, et al: Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer. 124:1358–1365. 2009. View Article : Google Scholar
9	Li BL, Lu W, Lu C, Qu JJ, Yang TT, Yan Q and Wan XP: CpG island hypermethylation-associated silencing of microRNAs promotes human endometrial cancer. Cancer Cell Int. 13:442013. View Article : Google Scholar : PubMed/NCBI
10	Dai Y, Xia W, Song T, Su X, Li J, Li S, Chen Y, Wang W, Ding H, Liu X, et al: MicroRNA-200b is overexpressed in endometrial adenocarcinomas and enhances MMP2 activity by downregulating TIMP2 in human endometrial cancer cell line HEC-1A cells. Nucleic Acid Ther. 23:29–34. 2013. View Article : Google Scholar :
11	Snowdon J, Zhang X, Childs T, Tron VA and Feilotter H: The microRNA-200 family is upregulated in endometrial carcinoma. PLoS One. 6:e228282011. View Article : Google Scholar : PubMed/NCBI
12	Hendriks SH, Schrijnders D, van Hateren KJ, Groenier KH, Siesling S, Maas AHEM, Landman GWD, Bilo HJG and Kleefstra N: Association between body mass index and obesity-related cancer risk in men and women with type 2 diabetes in primary care in the Netherlands: A cohort study (ZODIAC-56). BMJ Open. 8:e0188592018. View Article : Google Scholar : PubMed/NCBI
13	Flannery CA, Saleh FL, Choe GH, Selen DJ, Kodaman PH, Kliman HJ, Wood TL and Taylor HS: Differential expression of IR-A, IR-B and IGF-1R in endometrial physiology and distinct signature in adenocarcinoma. J Clin Endocrinol Metab. 101:2883–2891. 2016. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
15	Zhang Y, He X, Liu Y, Ye Y, Zhang H, He P, Zhang Q, Dong L, Liu Y and Dong J: [Corrigendum] MicroRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer. Oncol Rep. 33:20932015. View Article : Google Scholar
16	Yao J, Liang LH, Zhang Y, Ding J, Tian Q, Li JJ and He XH: GNAI1 suppresses tumor cell migration and invasion and is post-transcriptionally regulated by Mir-320a/c/d in hepatocellular carcinoma. Cancer Biol Med. 9:234–241. 2012.
17	van der Kolk JH, Pacholewska A and Gerber V: The role of microRNAs in equine medicine: A review. Vet Q. 35:88–96. 2015. View Article : Google Scholar : PubMed/NCBI
18	Wang J, Shi C, Wang J, Cao L, Zhong L and Wang D: MicroRNA-320a is downregulated in non-small cell lung cancer and suppresses tumor cell growth and invasion by directly targeting insulin-like growth factor 1 receptor. Oncol Lett. 13:3247–3252. 2017. View Article : Google Scholar : PubMed/NCBI
19	Guo T, Feng Y, Liu Q, Yang X, Jiang T, Chen Y and Zhang Q: MicroRNA-320a suppresses in GBM patients and modulates glioma cell functions by targeting IGF-1R. Tumour Biol. 35:11269–11275. 2014. View Article : Google Scholar : PubMed/NCBI
20	Sianou A, Galyfos G, Moragianni D, Andromidas P, Kaparos G, Baka S and Kouskouni E: The role of microRNAs in the pathogenesis of endometrial cancer: A systematic review. Arch Gynecol Obstet. 292:271–282. 2015. View Article : Google Scholar : PubMed/NCBI
21	Carroll AP, Goodall GJ and Liu B: Understanding principles of miRNA target recognition and function through integrated biological and bioinformatics approaches. Wiley Interdiscip Rev RNA. 5:361–379. 2014. View Article : Google Scholar : PubMed/NCBI
22	Diakos C, Zhong S, Xiao Y, Zhou M, Vasconcelos GM, Krapf G, Yeh RF, Zheng S, Kang M, Wiencke JK, et al: TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a. Blood. 116:4885–4893. 2010. View Article : Google Scholar : PubMed/NCBI
23	Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, Srinivasan R, Trimboli AJ, Martin CK, Li F, et al: Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol. 14:159–167. 2011. View Article : Google Scholar : PubMed/NCBI
24	Chen L, Zheng J, Zhang Y, Yang L, Wang J, Ni J, Cui D, Yu C and Cai Z: Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. Mol Ther. 19:1521–1528. 2011. View Article : Google Scholar : PubMed/NCBI
25	Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, Sohn-Lee C, le Sage C, Agami R, Tuschl T and Holland EC: The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 23:1327–1337. 2009. View Article : Google Scholar : PubMed/NCBI
26	Shu S, Yang Y, Li X, Li T, Zhang Y, Xu C, Liang C and Wang X: Down-regulation of IGF-1R expression inhibits growth and enhances chemosensitivity of endometrial carcinoma in vitro. Mol Cell Biochem. 353:225–233. 2011. View Article : Google Scholar : PubMed/NCBI
27	Shu S, Li X, Yang Y, Zhang Y, Li T, Liang C and Wan J: Inhibitory effect of siRNA targeting IGF-1R on endometrial carcinoma. Int Immunopharmacol. 11:244–249. 2011. View Article : Google Scholar